SCHEMBL7181124

SCHEMBL7181124

O=S(=O)(Nc1ccc(C2=NCCc3ccc(Cl)cc32)cc1)c1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 3/20 0.46
ITGA1 P56199 3/20 0.44
MCL1 Q07820 1/20 0.43
PPARG P37231 5/20 0.42
CYP3A4 P08684 1/20 0.42
IDH1 O75874 2/20 0.42
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
CCNA2 P20248 1/20 0.40
CCND1 P24385 1/20 0.40
CDK2 P24941 1/20 0.40
CDK7 P50613 1/20 0.40
CCNH P51946 1/20 0.40
CCNA1 P78396 1/20 0.40
CDK6 Q00534 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715063 0.94 SGK1 (0.46) SGK1ITGA1MCL1PPARGCYP3A4
SCHEMBL6715037 0.93 SGK1 (0.45) SGK1MCL1PPARGCYP3A4IDH1
SCHEMBL6718780 0.91 SGK1 (0.47) SGK1ITGA1MCL1PPARGCYP3A4
SCHEMBL6724899 0.91 SGK1 (0.48) SGK1ITGA1MCL1PPARGCYP3A4
SCHEMBL6717790 0.91 CDK1 (0.47) SGK1ITGA1MCL1PPARGCYP3A4
SCHEMBL6718381 0.88 SGK1 (0.45) SGK1MCL1PPARGCYP3A4IDH1
SCHEMBL6716678 0.87 ITGA1 (0.46) SGK1ITGA1PPARGMEN1LMNA
SCHEMBL6718834 0.86 SGK1 (0.47) SGK1MCL1PPARGCYP3A4CDK1
SCHEMBL7124579 0.85 KDM1A (0.48) MEN1LMNAMAPTKMT2A
SCHEMBL6720522 0.84 CDK1 (0.47) SGK1ITGA1MCL1PPARGCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A SGK1 4293/4885ITGA1 4550/4885MCL1 4558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.